AnaptysBio (NASDAQ:ANAB) Given New $30.00 Price Target at Truist Financial

AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price lifted by equities researchers at Truist Financial from $20.00 to $30.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Truist Financial’s target price points to a potential downside of 13.42% from the […]

Leave a Reply

Your email address will not be published.

Previous post HC Wainwright Cuts Iterum Therapeutics (NASDAQ:ITRM) Price Target to $5.00
Next post Revance Therapeutics (NASDAQ:RVNC) Stock Rating Lowered by Piper Sandler